文献速递免疫规划

江苏省2017至2019年EV71灭活疫苗上市后安全性监测

Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019.
PubMed 文献 · Vaccine · 2021-02-01

基于中国AEFI信息系统和电子免疫登记系统,分析了江苏省2017至2019年EV71灭活疫苗的AEFI报告。2017、2018、2019年分别报告209、407、344例AEFI,报告发生率分别为每10万剂59.2、48.2、54.2。常见AEFI为发热、烦躁、过敏性皮疹等,两类型疫苗间罕见反应无显著差异,多数AEFI发生在接种后30分钟至3天内。

要点

  • EV71疫苗上市后AEFI报告发生率约48.2-59.2/10万剂。
  • 常见AEFI为发热、烦躁、过敏性皮疹、乏力、食欲不振等。
  • 两类型EV71疫苗间罕见反应无显著差异,多数AEFI轻微。

核心结论

  • EV71疫苗在江苏省首次使用3年来显示出满意的安全性,AEFI谱与上市前研究一致,多数AEFI轻微且常见。

研究设计与样本

  • 利用中国AEFI信息系统和电子免疫登记系统,收集2017至2019年江苏省EV71疫苗接种后的AEFI报告和接种剂次,计算报告发生率并比较两类型疫苗。

主要发现

  • 2017、2018、2019年分别报告209、407、344例AEFI,报告发生率分别为每10万剂59.2、48.2、54.2。
  • 常见AEFI包括发热、烦躁、过敏性皮疹、乏力、食欲不振、注射部位红肿和硬结。
  • 两类型EV71疫苗间罕见反应无显著差异。
  • 多数AEFI发生在接种后30分钟至3天内。

临床怎么用

  • 接种EV71疫苗后应关注30分钟至3天内的常见轻微反应,无需过度担忧罕见反应。

局限性

  • 需开展更多主动监测研究以提供更全面的上市后安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Two types of enterovirus 71 (EV71) vaccines, manufactured using human diploid (H2) and Vero cells, have been administered in Jiangsu Province, China since 2017. In this study, we evaluated their safety profiles using records collected from the Chinese National Adverse Events Following Immunization (AEFIs) Information System (CNAEFIS) and Electronic Immunization Registries System (EIRS) between 2017 and 2019. METHODS: Demographic characteristics of the patients, AEFI incidence rates(IRs), symptoms, and time intervals were summarized from the reported AEFI data in the CNAEFIS. Also, the administered doses of the two vaccines were exported from the EIRS to calculate the IRs of AEFIs and thus compare the AEFIs between the two types of EV71 vaccines. RESULTS: In total, 209, 407, and 344 AEFIs cases following EV71 vaccine administration were reported during 2017, 2018, and 2019, respectively, yielding IRs of 59.2, 48.2, and 54.2 per 100,000 doses, respectively. Fever, irritability, allergic eruptions, fatigue, loss of appetite, redness and induration at the injection site were the most commonly reported AEFIs. No significant differences in rare reactions were found between the two types of EV71 vaccinations. The majority of AEFIs were developed within 30 min to 3 days after administration. CONCLUSION: EV71 vaccines showed satisfactory safety profiles since their first use 3 years ago in the Jiangsu Province. The AEFI profiles were identical to those in pre-marketing studies; most AEFIs after vaccination were mild and common. More active surveillance studies should be performed to provide more comprehensive post-marketing safety data.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gao J, Tang F, Wang Z, et al. Post-marketing safety surveillance for inactivated Enterovirus 71 vaccines in Jiangsu, China from 2017 to 2019. Vaccine. 2021. PMID: 33541795. doi:10.1016/j.vaccine.2021.01.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。